Reference health
Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia
00080-6/badge.svg){kind=icon}
22/22 checkable references clean · checked 2026-08-09
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
6 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 22 checked references that resolve
resolves10.1182/blood.V99.9.3472
High frequency of point mutations clustered within the adenosine triphosphate–binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance
resolves10.1126/science.2406902
Induction of Chronic Myelogenous Leukemia in Mice by the P210
<sup>
<i>bcr/abl</i>
</sup>
Gene of the Philadelphia Chromosome
resolves10.1056/NEJM200104053441402
Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome
resolves10.1056/NEJM200104053441401
Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
resolves10.1016/S0163-7258(99)00005-4
Inhibitors of Protein KinasesCGP 41251, a Protein Kinase Inhibitor with Potential as an Anticancer Agent
resolves10.1126/science.1062538
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
resolves10.1038/sj.onc.1203354
Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines
resolves10.1056/NEJMoa011573
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
resolves10.1097/00001622-200201000-00003
Comprehensive genotypic analysis of leukemia: clinical and therapeutic implications
resolves10.1182/blood.V99.1.310
FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model
resolves10.1016/S1535-6108(02)00070-3
CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML)
resolves10.1182/blood.V99.11.3885
A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo
resolves10.1182/blood.V98.3.885
A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations
resolves10.1200/JCO.2001.19.5.1485
Phase I and Pharmacokinetic Study of PKC412, an Inhibitor of Protein Kinase C
resolves10.1182/blood.V99.10.3530
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study
resolves10.1126/science.289.5486.1938
Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase
resolves10.1182/blood.V99.6.1928
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study
resolves10.1016/S0140-6736(02)07679-1
BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study
resolves10.1016/S1535-6108(02)00069-7
Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412
resolves10.1182/blood.V97.8.2434
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies
The 6 references without a DOI — listed, not checked
no DOI — not checked10.1016/S1535-6108(02)00080-6_BIB6
no DOI — not checked10.1016/S1535-6108(02)00080-6_BIB7
no DOI — not checked10.1016/S1535-6108(02)00080-6_BIB15
no DOI — not checked10.1016/S1535-6108(02)00080-6_BIB18
no DOI — not checkedO'Farrell, A.M., Abrams, T., Yuen, H., Ngai, T., Louie, S., Wong, L., Heinrich, M., Yee, K., Smolich, B., Murray, L., et al. (2001). SUGEN compounds SU5416 and SU11248 inhibit Flt3 activity: therapeutic application in AML. American Society of Hematology 43rd Annual Meeting, Orlando, Florida.
no DOI — not checkedYee, K.W.H., O'Farrell, A.M., Smolich, B.D., Cherrington, J.M., Wait, C.L., Griffith, D.J., McGreevey, L.S., Heinrich, M.C. (2001). SU5416 and SU5614 Inhibit Wild-Type and Activated Mutant FLT3 Signaling in Leukemia Cells. American Society of Hematology 43rd Annual Meeting, Orlando, Florida.
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-08-09 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1016/s1535-6108(02)00080-6"><img src="https://citestamp.com/citestamped/10.1016/s1535-6108(02)00080-6/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[00080-6/badge.svg)](https://citestamp.com/citestamped/10.1016/s1535-6108(02)00080-6)